Daptomycin vs Nisin
Research Verdict
Daptomycin is the stronger research reference for the stated comparison criteria. Daptomycin (Cubicin): FDA approved for complicated skin infections and S.
Quick Answers
Which is better, Daptomycin or Nisin?
Daptomycin is the stronger research reference for the stated comparison criteria. Daptomycin (Cubicin): FDA approved for complicated skin infections and S.
What is the key difference between Daptomycin and Nisin?
Daptomycin is inactivated by pulmonary surfactant (cannot treat pneumonia); nisin is a lantibiotic with >70 years of negligible resistance development - a remarkable distinction in the antimicrobial resistance landscape.
Evidence Comparison
Daptomycin (Cubicin): FDA approved for complicated skin infections and S. aureus bacteremia, extensive Phase 3 data and post-marketing surveillance. Nisin: GRAS food preservative since the 1950s, strong safety record, emerging preclinical therapeutic data but no clinical antibiotic trials. Daptomycin vastly stronger as a therapeutic.
Evidence Context Favoring Daptomycin
Clinical treatment of MRSA bacteremia or complicated skin infections where FDA-approved therapy is required.
Evidence Context Favoring Nisin
Food safety applications or antimicrobial resistance research where the rarity of nisin resistance after decades of use is scientifically relevant.
Side-by-Side Snapshot
| Evidence grade | Daptomycin: Level A Nisin: Level C |
|---|---|
| Research status | Daptomycin: FDA Approved Nisin: Preclinical |
| Primary category | Daptomycin: Immune Support Nisin: Immune Support |
| Cited studies | Daptomycin: 3 Nisin: 3 |